Search Results | Clinical Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley, Geoffrey I. Shapiro, Viktor Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos, Alan D'Andrea, Elizabeth M. Swisher, Ursula A. Matulonis, Gerburg M. Wulf, Erica L. Mayer

Clin Cancer Res (2022) 28 (8): 1493–1499.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-3045

Published: 14 April 2022

View article

Includes: Supplementary data

Journal Articles

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus S. Noel, Jennifer M. Suga, Ignacio Garrido-Laguna, Dana Backlund Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, Howard S. Hochster

Clin Cancer Res (2021) 27 (23): 6314–6322.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-1789

Published: 01 December 2021

View article

Includes: Supplementary data

Journal Articles

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, James W. Hodge, Andrew B. Nixon, Erin Nichols, Mohammad H. Bagheri, Elliott Levy, Marc R. Radke, Stanley Lipkowitz, Christina M. Annunziata, Janis M. Taube, Seth M. Steinberg, Jung-Min Lee

Clin Cancer Res (2020) 26 (16): 4268–4279.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-0056

Published: 14 August 2020

View article

Includes: Supplementary data

Journal Articles

Abstract IA02: DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response

Clin Cancer Res (2020) 26 (13_Supplement): IA02.

DOI: https://doi.org/10.1158/1557-3265.OVCA19-IA02

Published: 01 July 2020

View article

Journal Articles

Abstract B40: Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian cancer

Jeffrey D. Krimmel-Morrison, Shenyi Lian, Yuezheng Zhang, Jeanne Fredrickson, Daniela Nachmanson, Kathryn T. Baker, Marc R. Radke, Enna Hun, Barbara Norquist, Mary J. Emond, Elizabeth M. Swisher, Rosa Ana Risques

Clin Cancer Res (2020) 26 (13_Supplement): B40.

DOI: https://doi.org/10.1158/1557-3265.OVCA19-B40

Published: 01 July 2020

View article

Journal Articles

Abstract AP22: DNA DAMAGE RESPONSES AND IMMUNE PROFILING THROUGH HIGHLY MULTIPLEXED TISSUE IMMUNOFLUORESCENCE (T-CYCIF) IN HIGH-GRADE SEROUS OVARIAN CANCER

Anniina Färkkilä, Jia-Ren Lin, Zoltan Maliga, Sameer S. Chopra, Bose Koruchupakkal, Brooke E. Howitt, Kyle C. Strickland, Sandro Santagata, Elizabeth M. Swisher, Ursula A. Matulonis, Jennifer. L. Guerriero, Kevin Elias, Panagiotis Konstantinopoulos, Peter K. Sorger, Alan D. D'Andrea

Clin Cancer Res (2019) 25 (22_Supplement): AP22.

DOI: https://doi.org/10.1158/1557-3265.OVCASYMP18-AP22

Published: 15 November 2019

View article

Journal Articles

Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS

Clin Cancer Res (2019) 25 (22_Supplement): AP10.

DOI: https://doi.org/10.1158/1557-3265.OVCASYMP18-AP10

Published: 15 November 2019

View article

Journal Articles

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

Clin Cancer Res (2018) 24 (4): 777–783.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1327

Published: 14 February 2018

View article

Includes: Supplementary data

Journal Articles

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

Clin Cancer Res (2018) 24 (4): 744–752.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1590

Published: 01 February 2018

View article

Includes: Supplementary data

Journal Articles

Abstract AP29: BRCA1 RING DOMAIN–DEFICIENT PROTEINS PROMOTE PARP INHIBITOR AND PLATINUM RESISTANCE

Yifan Wang, John J. Krais, Andrea J. Bernhardy, Emmanuelle Nicolas, Kathy Q. Cai, Maria I. Harrell, Hyoung H. Kim, Erin George, Elizabeth M. Swisher, Fiona Simpkins, Neil Johnson

Clin Cancer Res (2017) 23 (11_Supplement): AP29.

DOI: https://doi.org/10.1158/1557-3265.OVCASYMP16-AP29

Published: 31 May 2017

View article

Journal Articles

Abstract IS04: PARP INHIBITOR COMBINATIONS FOR THE TREATMENT OF OVARIAN CANCER

Scott H. Kaufmann, Andrea E. Wahner Hendrickson, Maria I Harrell, Michael E. Menefee, Edward J. Tanner, David G Mutch, Elizabeth M. Swisher, Larry M. Karnitz

Clin Cancer Res (2017) 23 (11_Supplement): IS04.

DOI: https://doi.org/10.1158/1557-3265.OVCASYMP16-IS04

Published: 31 May 2017

View article

Journal Articles

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Elizabeth M. Swisher

Clin Cancer Res (2016) 22 (23): 5651–5660.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-0247

Published: 30 November 2016

View article

Includes: Supplementary data

Journal Articles

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms

Keith W. Pratz, Brian D. Koh, Anand G. Patel, Karen S. Flatten, Weijie Poh, James G. Herman, Robert Dilley, Maria I. Harrell, B. Douglas Smith, Judith E. Karp, Elizabeth M. Swisher, Michael A. McDevitt, Scott H. Kaufmann

Clin Cancer Res (2016) 22 (15): 3894–3902.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-2351

Published: 31 July 2016

View article

Includes: Supplementary data

Journal Articles

Abstract B36: In vivo laser-based imaging of the human fallopian tube for future cancer detection.

Elizabeth M. Swisher, C. David Melville, Richard S. Johnston, Kathy Agnew, Seine Chiang, Eric J. Seibel

Clin Cancer Res (2016) 22 (2_Supplement): B36.

DOI: https://doi.org/10.1158/1557-3265.OVCA15-B36

Published: 15 January 2016

View article

Journal Articles

Abstract A07: Homologous recombination mutations and overall survival in high-grade serous, endometrioid, and clear cell ovarian carcinomas.

Maria I. Harrell, Matthew J. Maurer, Ethan P. Heinzen, Ming K. Lee, Kimberly R. Kalli, Kathy J. Agnew, Ann L. Oberg, Tom Walsh, Barbara M. Norquist, Lynn C. Hartmann, Scott H. Kaufmann, Elizabeth M. Swisher

Clin Cancer Res (2016) 22 (2_Supplement): A07.

DOI: https://doi.org/10.1158/1557-3265.OVCA15-A07

Published: 15 January 2016

View article

Journal Articles

Abstract B71: Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer.

Maria I. Harrell, Barbara M. Norquist, Tom Walsh, Mark F. Brady, Ming K. Lee, Robert Hershberg, Kimberly R. Kalli, Heather Lankes, Eric Q. Konnick, Colin C. Pritchard, Bradley J. Monk, John K. Chan, Robert Burger, Scott H. Kaufmann, Michael J. Birrer, Elizabeth M. Swisher

Clin Cancer Res (2016) 22 (2_Supplement): B71.

DOI: https://doi.org/10.1158/1557-3265.OVCA15-B71

Published: 15 January 2016

View article

Journal Articles

Abstract A12: Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology Study.

Barbara M. Norquist, Mark F. Brady, Maria I. Harrell, Tom D. Walsh, Ming K. Lee, Suleyman Gulsuner, Sarah S. Bernards, Silvia Casadei, Robert A. Burger, Susan A. Davidson, Robert S. Mannel, Paul A. DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary Claire King, Michael J. Birrer, Elizabeth M. Swisher

Clin Cancer Res (2016) 22 (2_Supplement): A12.

DOI: https://doi.org/10.1158/1557-3265.OVCA15-A12

Published: 15 January 2016

View article

Journal Articles

DNA Repair Mutations and Outcomes in Ovarian Cancer—Response

Elizabeth M. Swisher, Barbara M. Norquist, Kathryn P. Pennington, Mara H. Rendi, Rochelle L. Garcia

Clin Cancer Res (2015) 21 (3): 659.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-2805

Published: 01 February 2015

View article

Journal Articles

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

Kathryn P. Pennington, Tom Walsh, Maria I. Harrell, Ming K. Lee, Christopher C. Pennil, Mara H. Rendi, Anne Thornton, Barbara M. Norquist, Silvia Casadei, Alexander S. Nord, Kathy J. Agnew, Colin C. Pritchard, Sheena Scroggins, Rochelle L. Garcia, Mary-Claire King, Elizabeth M. Swisher

Clin Cancer Res (2014) 20 (3): 764–775.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-2287

Published: 02 February 2014

View article

Includes: Supplementary data

NARROW

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Abstract IA02: DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response

Abstract B40: Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian cancer

Abstract AP22: DNA DAMAGE RESPONSES AND IMMUNE PROFILING THROUGH HIGHLY MULTIPLEXED TISSUE IMMUNOFLUORESCENCE (T-CYCIF) IN HIGH-GRADE SEROUS OVARIAN CANCER

Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

Abstract AP29: BRCA1 RING DOMAIN–DEFICIENT PROTEINS PROMOTE PARP INHIBITOR AND PLATINUM RESISTANCE

Abstract IS04: PARP INHIBITOR COMBINATIONS FOR THE TREATMENT OF OVARIAN CANCER

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms

Abstract B36: In vivo laser-based imaging of the human fallopian tube for future cancer detection.

Abstract A07: Homologous recombination mutations and overall survival in high-grade serous, endometrioid, and clear cell ovarian carcinomas.

Abstract B71: Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer.

Abstract A12: Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG Oncology Study.

DNA Repair Mutations and Outcomes in Ovarian Cancer—Response

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only